50 results about "Immunological diseases" patented technology

The present invention relates to compounds having cyclin-dependent kinase (CDK)-inhibitory functions and / or pharmaceutically acceptable salts thereof, the use of these compounds as pharmaceutically active agents, especially for the prophylaxis and / or treatment of cell proliferative diseases, inflammatory diseases, immunological diseases, cardiovascular diseases and infectious diseases. Furthermore, the present invention is directed towards pharmaceutical compositions containing such compounds.

A compound represented by general formula (I) or a pharmaceutically acceptable salt or a stereoisomer thereof, and a use thereof in treating diseases such as tumors, immunological diseases, and inflammatory diseases, as well as a pharmaceutical preparation and a pharmaceutical composition of the compound, and a use thereof.

The disclosure provides, in various embodiments, compositions, such as polypeptides, polynucleotides, gene editing system, small molecules, vectors or host cells, that comprises and / or modulate expression or activity of immune regulation-associated proteins. The disclosure also provides, in various embodiments, methods of treating aging, senescence, fibrosis, a metabolic disease, cardiovascular disease, an endocrine-associated disorder, a genetic disease, cancer, an infection, an immunological disease, an indication treated with hormone, growth factor and / or protein replacement, or a combination thereof using an agent that comprises and / or modulates expression or activity of an immune regulation-associated protein and methods of identifying said agent.

The present invention provides a novel multi-strain probiotic formulation and relates to the use of the multi-strain formulation in therapy, in particular for the treatment or prevention of immunological or allergic diseases / disorders, such as allergic rhinitis or allergic conjunctivitis. In addition, the present invention also provides a novel therapeutic regimen that is easy to follow using the probiotic formulations provided herein.

Provided is a novel camptothecin derivative or a conjugate thereof, and a preparation method therefor and an application thereof in medicine. Specifically, provided is a compound represented by general formula (A) or a ligand-drug conjugate thereof, a preparation method therefor, and an application of the ligand-drug conjugate and a pharmaceutical composition thereof in the preparation of a drug for the treatment of cancer or immunological diseases.

Defined herein are immunomodulating Formula (1) compounds, wherein R, R0, R1, R2and W are as defined herein, stereoisomers thereof, and pharmaceutically acceptable salts thereof; and compositions comprising said compounds. The invention also includes methods for treating or preventing an inflammatory and / or immunological disease or disorder in an animal by administering a therapeutically effective amount of a Formula (1) compound, stereoisomer thereof, or pharmaceutically acceptable salt thereof; or use of said Formula (1) compound to prepare a medicament for treating or preventing an inflammatory and / or immunological disease or disorder in an animal.

The invention relates to the field of medicinal chemistry and medicine, and discloses pentacyclic triterpene derivatives and application thereof in prevention and / or treatment of immune diseases. The pentacyclic triterpene derivative disclosed by the invention has a structure as shown in a formula (I) and has an excellent immunoregulation effect on Tc1, Tc17 and Th17 cells, and the invention also provides application of the compound in preparation of medicines for preventing and / or treating immune diseases.

The invention relates to the technical field of molecular immunology and biology, in particular to a sicca syndrome model mouse B cell immune repertoire sequencing and subpopulation analysis method. The method comprises the following steps: S1, sample preparation: preparing a single-cell suspension from a target autoimmune disease animal model and a preset tissue of a control animal, and carrying out B cell enrichment treatment on the single-cell suspension to obtain a B cell sample; s2, multi-dimensional data parallel analysis: analyzing the B cell sample, and performing parallel construction of the multi-dimensional data; and S3, integrated correlation analysis: carrying out correlation analysis on the immune group library data, the cell subset data and the signal channel data obtained in the step S2 to establish a correlation relationship among specific B cell cloning characteristics, specific B cell subset changes and specific signal channel activity, and carrying out multilevel analysis and generating a B cell immune response mechanism of the autoimmune disease. The efficiency and accuracy of disease mechanism research and drug action mechanism evaluation are remarkably improved.

The invention provides methods for assessing immune system function and status based on cellular analysis. Methods of the present invention involve obtaining mass properties of immune cells collected in a tissue or body fluid sample from a subject. Such mass properties may include the mass of one or more immune cells and / or changes in mass of such immune cells over a period of time. Such data is then used for determining a status of the subject's immune response, and subsequent diagnosis and treatment of an infection or immunological disease or dysfunction.

This invention provides a device for applying ointments for rheumatic and immunological diseases, comprising a box body with an ointment chamber at the top and a buffer chamber inside the box body, the buffer chamber having a flat opening; a control rod rotatably connected to the inner cavity of the buffer chamber, a buffer plate being provided on one side of the control rod, and a first spring connecting the buffer plate and the buffer chamber; a conveyor plate rotatably mounted inside a cylindrical chamber, the conveyor plate having multiple transfer grooves evenly distributed around its circumference; a first tube being provided on the top side of the cylindrical chamber and a second tube being provided on the bottom side; a drive mechanism capable of driving the conveyor plate to rotate. The ointment continuously flowing into the buffer chamber pushes the buffer plate towards the bottom of the buffer chamber, and the first spring also provides an elastic force that pushes the buffer plate upwards. Under the mutual pushing action of the ointment and the buffer plate, the ointment is compressed, reducing gaps and air bubbles, and is discharged from the flat opening, resulting in a uniform and dense ointment without gaps, eliminating the need for secondary coating and repair, and reducing drug waste while ensuring drug absorption.

The present invention relates to novel immunoregulatory macrophage cells which are useful in the treatment of different immunological and non-immunological diseases and conditions. The cells are characterized by a specific marker and activity pattern which distinguishes them from other cells. The invention also provides a process for preparing the immunoregulatory macrophage cells from blood monocytes. In a still further aspect, the invention relates to a pharmaceutical composition comprising the immunoregulatory macrophage cells of the invention or a sub-cellular fraction thereof. A process for preparing a sub-cellular fraction of an immunoregulatory macrophage cell of the invention is also provided.

A pharmaceutical use of a pharmaceutical composition containing platinum drugs or platinum drug co-crystals as main active substances in preventing or treating immunological diseases such as rheumatoid arthritis, and other diseases. The platinum drugs mainly refer to oxaliplatin, and the platinum drug co-crystals mainly refer to carboplatin co-crystals or oxaliplatin co-crystals. Further disclosed is a method using platinum drugs or platinum drug co-crystals, either alone or in combination with at least one additional therapeutic agent or adjuvant therapy agent.

The application relates to the field of medical devices, in particular to a joint protection device suitable for children with rheumatic and immunological diseases, which comprises a joint protection sleeve, a plurality of first sliding grooves and a plurality of connecting rods are arranged on the two sides of the joint protection sleeve, the first sliding grooves and the connecting rods are in one-to-one correspondence, when the joint protection sleeve wraps the joint, the connecting rods are inserted into the first sliding grooves, and the connecting rods and the first sliding grooves are in sliding cooperation; the adjusting holes and the anti-occlusion mechanisms are communicated in the first sliding grooves, the opening and closing mechanisms are communicated on the communication paths of the adjusting holes and the first sliding grooves, and the opening and closing mechanisms are used for controlling the on-off of the adjusting holes and the first sliding grooves; the anti-occlusion mechanisms are used for connecting the first sliding grooves with the outside based on the negative pressure size in the first sliding grooves. The application can realize dynamic adaptation and intelligent protection, and reduce the occlusion risk caused by rigid fixation of the device.

The invention provides a polypeptide and application thereof in preparation of an immunomodulatory product. It is found that the polypeptide with the amino acid sequence shown as SEQ ID NO: 1 can significantly improve the secretion amount of macrophage inflammatory factors and the ROS generation amount, enhance immunity, significantly reduce the influence of LPS on macrophage NO release and inflammatory factor secretion and repair immune imbalance caused by excessive inflammation, and it is indicated that the polypeptide has excellent immunoregulation activity and can be used for preparing immunomodulatory drugs for treating the macrophage NO release and inflammatory factor secretion. In other words, the polypeptide is suitable for preparing products for enhancing immunity, immunoregulation products and drugs for preventing and / or treating immune diseases.

To provide methods for preparing compositions enriched in T regulatory cells (Tregs) and methods for treating immunological diseases using the compositions, and to provide methods for preparing compositions enriched in lymphocytes and depleted of Tregs and use of the compositions in treating proliferative diseases.SOLUTION: A method for preparing a composition enriched in CD4+CD25hi T regulatory cells (Tregs) is provided, comprising contacting in vitro a population of human cells including T lymphocytes obtained from a patient-derived human blood or bone marrow sample with a tumor necrotic factor receptor 2 (TNFR2) agonist or an NF-κB activator, thereby preparing the composition in which the Tregs are enriched, wherein the Tregs constitute at least 60% of the cells in the composition.SELECTED DRAWING: None

Abstract Provided herein are multi-domain immunomodulatory proteins, nucleic acids encoding such immunomodulatory proteins, cells engineered to express the immunomodulatory proteins and infectious agents containing nucleic acid encoding the immunomodulatory proteins. The immunomodulatory proteins bind both an inhibitory receptor and a receptor involved in activation signaling cascades in an immune cell, such as a T cell. The immunomodulatory proteins, engineered cells and infectious agents provide therapeutic utility for a variety of immunological diseases or conditions. Compositions and methods for making and using such proteins are provided. Abstract 20 26 21 41 08 10 A ug 2 02 6 A b s t r a c t 2 0 2 6 2 1 4 1 0 8 1 0 A u g 2 0 2 6

The disclosure provides, in various embodiments, compositions, such as polypeptides, polynucleotides, gene editing systems, small molecules, vectors or host cells, that comprise and / or modulate expression or activity of immune regulation-associated proteins, such as cytokines. The disclosure also provides, in various embodiments, methods of treating inflammation, aging, senescence, fibrosis, autoimmunity, cancer, an infection, and / or an immunological disease using an agent that comprises and / or modulates expression or activity of an immune regulation-associated protein, and methods of identifying said agent.

The present invention introduces a novel immunotherapeutic approach utilizing dual-targeting cancer cell therapy. This therapy involves dual -targeting constructs that co-express either chimeric antigen receptors (CARs) alone or a CAR with a bispecific T-cell engagers (BiTEs) to target two distinct antigens. This innovative design minimizes antigen escape and enhances cytotoxic efficacy by harnessing the advantages of both CAR-T cells and BiTEs. Additionally, the invention discloses the use of bidirectional or in-line promoters to co-regulate the expression of dual CARs or co-expression of a CAR and a BiTE. It also provides polynucleotide and amino acid sequences for these dual -targeting CAR constructs, with or without BiTEs, for the treatment of B-cell malignancies, autoimmune disorders, and other B cell-related diseases.

The invention relates to the technical field of joint puncture, in particular to an ultrasonic-guided joint puncture device for rheumatism immune disease diagnosis, which comprises a supporting seat, an electric sliding rail is mounted at the lower end of the supporting seat, a first sliding seat slides on the upper surface of the electric sliding rail, and a second sliding seat slides at the upper end of the first sliding seat. The upper surface of the second sliding seat is slidably connected with a positioning ring, two sets of guide buckles are installed at the lower end of the second sliding seat, and sliding rods are slidably arranged in the two sets of guide buckles. The puncture position and the diagnosis position are kept consistent, diagnosis errors or tissue damage risks caused by puncture deviation are reduced, and meanwhile, through scale marks on the outer sides of the two sets of sliding rods, medical staff can visually observe the puncture depth of the puncture needle through the displacement of the two sets of sliding rods in the limiting ring.

Defined herein are immunomodulating Formula (1) compounds, wherein R1, R2 and W are as defined herein, stereoisomers thereof, and pharmaceutically acceptable salts thereof; and compositions comprising said compounds. The invention also includes methods for treating an inflammatory and / or immunological disease or disorder in an animal by administering a therapeutically effective amount of a Formula (1) compound, stereoisomer thereof, and a pharmaceutically acceptable salt thereof; or use of said compound of Formula (1) to prepare a medicament for treating an inflammatory and / or immunological disease or disorder in an animal.

The invention is based on an adhesive composition comprising amylopectin, mastic gum, and at least one solvent, such as water and / or an alcoholic solvent, for example ethanol, optionally further comprising glycerol and / or sodium chloride. The invention also pertains to an adhesive, obtainable from an adhesive composition according to this invention, wherein the adhesive is a conductive or a non-conductive adhesive. The invention also pertains to a method for preparing and / or obtaining an adhesive composition or an adhesive, and to an adhesive composition or an adhesive obtainable by the method according to this invention. An adhesive composition or an adhesive for use in medicine, and an adhesive composition or an adhesive for use in a method of preventing and / or treating a disease, such as a cardiological disease, a neurological disease, an oncological disease, a vascular disease, an immunological disease, a carcinoid, and / or an infectious disease, is also provided.

The present invention relates to a polypeptide comprising Omomyc, a functionally equivalent variant thereof, a conjugate comprising Omomyc or said functionally equivalent variant, a polynucleotide encoding said polypeptides, a vector comprising said polynucleotide, and a cell capable of secreting the polypeptide or the conjugate for use in the prevention and / or treatment of an autoimmune disease. The invention also relates to combinations and pharmaceutical compositions of said compounds and at least a further compound useful in the treatment of an autoimmune disease, as well as their medical uses.

The present invention relates to a novel Lactobacillus plantarum IMB19 strain, polysaccharides derived from the strain and uses thereof. The novel Lactobacillus plantarum IMB19 strain and polysaccharides derived from the strain of the present invention exhibit superior CD8+ T cell activity stimulating capacity and Treg cell inhibitory activity and stimulate and improve anti-tumor immune responses through various mechanisms such as increasing macrophage infiltration in CPS tumors as well as macrophage differentiation and reprogramming into inflammatory phenotype (M1). Thus, the strain and polysaccharides derived from the strain of the present invention can be effectively used for immunomodulation, especially immune boosting, in a subject and can inhibit tumor growth by inducing and enhancing anti-tumor immune responses. The novel strain and polysaccharides derived from the strain of the present invention are useful for preventing, ameliorating or treating various immunological diseases such as tumors, infectious diseases and various immunological diseases caused by or as symptoms of immune dysfunction.

Abstract Provided herein are multi-domain immunomodulatory proteins, nucleic acids encoding such immunomodulatory proteins, cells engineered to express the immunomodulatory proteins and infectious agents containing nucleic acid encoding the immunomodulatory proteins. The immunomodulatory proteins bind both an inhibitory receptor and a receptor involved in activation signaling cascades in an immune cell, such as a T cell. The immunomodulatory proteins, engineered cells and infectious agents provide therapeutic utility for a variety of immunological diseases or conditions. Compositions and methods for making and using such proteins are provided. Abstract Provided herein are multi-domain immunomodulatory proteins, nucleic acids encoding such immunomodulatory proteins, cells engineered to express the immunomodulatory proteins and infectious agents containing nucleic acid encoding the immunomodulatory proteins. The immunomodulatory proteins bind both an inhibitory receptor and a receptor involved in activation signaling cascades in an immune cell, such as a T cell. The immunomodulatory proteins, engineered cells and infectious agents provide therapeutic utility for a variety of immunological diseases or conditions. Compositions and methods for making and using such proteins are provided. 20 24 20 45 59 01 J ul 2 02 4 2 0 2 4 2 0 4 5 5 9 0 1 J u l 2 0 2 4

A prodrug platform is useful to deliver pharmaceutically active amines, amides and phenols and their use in the diagnosis, prevention and / or treatment of various diseases. Compared with the parent drug (e.g., Gemcitabine), the prodrugs show a significant overall safety improvement (therapeutic index (TI) improvement), especially in liver. The prodrugs can treat several diseases, including, for example, cancer, metabolic disease, viral infection, immunological disease, neurologic disease, and blood disease.

The invention belongs to the technical field of biological medicine, and discloses a rheumatism immune disease intervention composition based on intestinal flora regulation and application of the composition. Comprising the following components in parts by weight: 10-20 parts of bifidobacterium triple viable bacterium freeze-dried powder, 30-50 parts of a dietary fiber compound, 5-15 parts of a plant extract active component, 2-8 parts of a microelement chelate and 10-30 parts of a pharmaceutically acceptable carrier. According to the composition, the probiotics, the prebiotics and the active ingredients are precisely compounded according to the intestinal flora imbalance characteristic of a patient suffering from the rheumatism immune disease, the composition directly acts on the intestine-liver axis, the immune system function is regulated from the source, and compared with a traditional medicine, the effect target is more precise, and the treatment effect is more remarkable.

Novel Styryl Carboxylate derivative compounds are provided which exhibit activity for the treatment of immunological diseases, inflammation, obesity, hyperlipidemia, hypertension, neurological diseases, and diabetes.

The present disclosure provides variant CD80 polypeptides that have altered affinity for their cognate binding partners, and immunomodulatory fusion proteins comprising the variant CD80 polypeptides. The present disclosure also provides pharmaceutical compositions comprising such polypeptides and / or proteins and methods for modulating immune responses and / or treatment of cancer, infectious diseases, and / or immunological diseases.

The present invention relates to: novel anti-TIGIT antibodies; and uses thereof for increasing immunity, anticancer treatments, and preventing and / or treating immunological diseases.